Double Protease Inhibitor to Darunavir Switch Study

NCT00531557 | Completed Phase 4

• 1 other identifier: SSAT022
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the study is to study the effects of switching from an antiretroviral combination that includes two ritonavir boosted protease inhibitors to replacement of these two protease inhibitors with a new protease inhibitor called Darunavir (also boosted with ritonavir). The study will investigate the effect of the switch on viral load (the levels of the HIV virus in the blood), on immunological parameters (CD4 count) and on other safety parameters and also on quality of life. In a subgroup of patients the impact of the switch on the body's response to the hormone insulin will also be measured (Euglycaemic clamp sub group)

Conditions

HIV Infections

Keywords

Darunavir; Euglycaemic clamp; HIV; Treatment Experienced

Outcome Measures

Primary Outcomes (1)

• The proportion of subjects maintaining viral suppression (< 50 copies/mL)

  48 weeks

Secondary Outcomes (1)

• • CD4+ count at screening, baseline, weeks 4, 12, 24, 36 and at the end of the study period • Viral suppression below 50 copies/mL and below 500 copies/mL at 4, 12, 24, 36 and 48 weeks • Laboratory abnormalities and adverse events at baseline, 4

  48 weeks

Study Arms (1)

1

OTHER

Darunavir 600mg BID with ritonavir 100mg BID administered orally.

Drug: Darunavir ritonavir

Interventions

Darunavir ritonavir DRUG

1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• HIV-1 infected as documented by a licensed HIV-1 antibody ELISA test
• At least 18 years of age
• Currently on an antiretroviral regimen including a ritonavir boosted double protease inhibitor
• The subject is virologically suppressed with a viral load \< 50 copies/mL for three months or longer
• The subject has a CD4+ count above 100 cells/mL
• ≤ Three DRV associated mutations on previous genotypic resistance test -or if no resistance test available, likely to have ≤ four protease inhibitor mutations based on their clinical history
• If the subject is a woman of child bearing potential, she must agree to use a barrier method of contraception
• The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements

You may not qualify if:

• Pregnant or lactating women
• Individuals with prior darunavir exposure
• Previous allergic or hypersensitivity reaction to darunavir
• Clinical or laboratory evidence of significantly decreased hepatic function or decompensation, irrespective of liver enzyme levels (liver insufficiency)
• Subjects diagnosed with acute viral hepatitis at screening
• Subjects with a grade 3 or 4 laboratory abnormality as defined by DAIDS grading table (see appendix 3: DAIDS AE grading Table), with the following exceptions unless clinical assessment foresees an immediate health risk to the subject:
• Subjects with pre-existing diabetes or with asymptomatic glucose grade 3 or 4 elevations
• Subjects with asymptomatic triglyceride or cholesterol elevations of grade 3 or 4.
• Presence of any currently active AIDS defining illness (Category C conditions according to the CDC Classification System for HIV Infection 1993) with the following exceptions: Stable cutaneous Kaposi's Sarcoma (i.e., no internal organ involvement other than oral lesions) that is unlikely to require any form of systemic therapy during the study; Wasting syndrome due to HIV infection.
• Note: An AIDS defining illness that is not clinically stabilized for at least 30 days will be considered as currently active.
• Active drug abuse, including alcohol or recreational drugs, which, in the opinion of the investigator, is expected to interfere with the subject's ability to adhere to the study procedures and treatment regimen. Subjects on a methadone program will be accepted if deemed appropriate by the investigator.

Sponsors & Collaborators

• St Stephens Aids Trust: lead

Study Sites (1)

St Stephens Centre, Chelsea & Westminster Hospital

London, United Kingdom

Location

MeSH Terms

Conditions

HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Study Officials

• Mark Nelson

  Chelsea & Westminser Healthcare NHS Trust

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: September 18, 2007
• First Posted: September 19, 2007
• Study Start: September 1, 2007
• Primary Completion: November 1, 2008
• Study Completion: November 1, 2008
• Last Updated: August 16, 2010

Record last verified: 2010-08

Locations

GB (1)